Alumis Inc.
ALMSHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Alumis Inc. focuses on Biotechnology services and products. Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The $3.65B market capitalization puts ALMS squarely in mid-cap range for its industry. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.
Market Cap
$3.65B
Beta
-0.71
P/E (TTM)
—
P/E (Fwd)
-9.70
EPS (TTM)
$-1.87
EPS (Fwd)
$-2.95
ROE
-64.6%
ROA
-58.8%
Cash
$522.9M
Total Debt
$35.7M
Free CF
-$206.8M
52W Change
760.7%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $522.9M in cash comfortably exceeding the $35.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$206.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -64.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
ALMS's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Alumis Inc. and its sector.